Stefan Wiemann
Has participated in:
-
Identification of transcription factors that specifically bind methylated recognition sites
-
GLYATL1, a Novel Player in Endocrine Therapy Resistance in Breast Cancer
-
Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance
-
Investigating the role of alanine aminotransferase 2 in breast cancer